Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation.

[1]  J. Ciezki,et al.  Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? , 2009, Urologic oncology.

[2]  W. Sega,et al.  Laparoscopic extended pelvic lymph node dissection for prostate cancer: description of the surgical technique and initial results. , 2007, European urology.

[3]  G. Lockwood,et al.  Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[4]  M. Kattan,et al.  The surgical learning curve for prostate cancer control after radical prostatectomy. , 2007, Journal of the National Cancer Institute.

[5]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[6]  M. Cooperberg,et al.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). , 2003, The Journal of urology.

[7]  S. Stokes,et al.  Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. , 2000, International journal of radiation oncology, biology, physics.

[8]  H. Sandler,et al.  Hormone therapy and radiotherapy for intermediate risk prostate cancer. , 2008, Seminars in radiation oncology.

[9]  Utilization and outcomes of minimally invasive radical prostatectomy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[11]  T. Keane,et al.  Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. , 2007, Urology.

[12]  L. Wilson,et al.  Surgery Versus Implant for Early Prostate Cancer: Results From a Single Institution, 1992–2005 , 2007, Cancer journal.

[13]  P. Scardino,et al.  An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow‐up , 2002, Cancer.

[14]  X. Cathelineau,et al.  Impact of learning curve in laparoscopic radical prostatectomy on margin status: prospective study of first 100 procedures performed by one surgeon. , 2004, Journal of endourology.

[15]  M. Kattan,et al.  Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy: Reply by authors , 1998 .

[17]  J. Ciezki,et al.  The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment. , 2010, Urology.

[18]  Kirsten L. Greene,et al.  Who is the average patient presenting with prostate cancer? , 2005, Urology.

[19]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[20]  J. Ciezki,et al.  A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. , 2004, International journal of radiation oncology, biology, physics.

[21]  Michael W Kattan,et al.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[23]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[24]  A. Heidenreich,et al.  Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. , 2007, European urology.

[25]  B. Guillonneau,et al.  Laparoscopic radical prostatectomy: contemporary comparison with open surgery. , 2007, Urologic oncology.

[26]  L. Potters,et al.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[27]  S Duke Herrell,et al.  Robotic-assisted laparoscopic prostatectomy: what is the learning curve? , 2005, Urology.

[28]  Anthony V D'Amico,et al.  Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.

[29]  A. Renshaw,et al.  Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. , 2000, JAMA.

[30]  Andrew J Vickers,et al.  The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. , 2009, The Lancet. Oncology.

[31]  L. Kavoussi,et al.  Tumor seeding in urological laparoscopy: an international survey. , 2004, The Journal of urology.

[32]  J. Crook,et al.  Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Ciezki,et al.  Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[34]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[35]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[36]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.